Page results
-
The cochlear implant programme was founded in 1982, and we were the first clinical cochlear implant programme in the UK. The team has been involved with the successful implantation of more than 2,000 patients, both adults and children, from all over the UK.
-
We are part of the MRC Centre for Neuromuscular Diseases and our team is actively involved in cutting-edge neuroscience research.
-
How to refer to infectious and tropical diseases.
-
This page has been written for patients who are having radiotherapy to the breast or chest wall area.
-
The Neuroimmunology and CSF Laboratory at the Institute of Neurology, UCLH is a UKAS accredited medical laboratory No. 8045.
-
This page is for parents, carers and relatives whose child is having radiotherapy treatment to the eye (orbit). There are different conditions that may require radiotherapy to the eye such as retinoblastoma, orbital rhabdomyosarcomas, soft tissue sarcomas, lymphomas, or some other condition.
-
CAR T-cell therapy is a cutting-edge treatment for certain blood cancers, offering new hope to patients whose illness hasn’t responded to standard treatments. University College London Hospitals (UCLH) is proud to be one of Europe’s leading centres for this advanced care.
-
Acute loss of sense of smell should be considered globally as a criterion for self-isolation, testing, and contact tracing for Covid-19 infection according to researchers at UCLH and UCL.
-
This page is for children and young people receiving Proton beam therapy. It explains what growth monitoring is and why it is important.
File results
-
FOI/2023/0146 - Total bed management contract with Medstrom
-
FOI/2023/0270 - Total agency spend and midwifery spend from 2018/19 to 2022/23
-
FOI/2023/0222 - Contact details for senior screening and immunisations staff
-
FOI/2023/0231 - Patients seen at A&E with symptoms of taking nitrous oxide gas
-
FOI/2023/0237 - Software solution to manage patient e-consent for school vaccinations/ immunisations and waitlist validation
-
FOI/2023/0250 - Early Access to Medicines Scheme (EAMS)
-
FOI/2023/0251 - Vials used for immunoglobulin drugs - January to March 2023
-
FOI/2023/0211 - Services available to older residents
-
FOI/2023/0332 - Eating disorder services and Advance Decisions/ Directives to refuse medical treatment (ADRTs)
-
FOI/2023/0188 - Payments to suppliers